Surefire Medical Launches Precision Targeted Infusion System

Westminster, Colo.-based Surefire Medical has introduced its Precision targeted delivery infusion system for direct-to-tumor embolization procedures.

The drug delivery system is designed to treat primary liver cancers, many of which are inoperable, by increasing drug delivery to tumors by as much as 90 percent, according to the company.

Surefire President and CEO James Chomas says the device controls pressure during drug delivery to overcome the barriers of high pressure and no blood flow.

The device has both CE mark and FDA clearance. — Michael Cipriano